US4272398A - Microencapsulation process - Google Patents

Microencapsulation process Download PDF

Info

Publication number
US4272398A
US4272398A US06/049,019 US4901979A US4272398A US 4272398 A US4272398 A US 4272398A US 4901979 A US4901979 A US 4901979A US 4272398 A US4272398 A US 4272398A
Authority
US
United States
Prior art keywords
compound
aggregates
polymer
solution
microcapsules
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US06/049,019
Inventor
Howard Jaffe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Agriculture USDA
Original Assignee
US Department of Agriculture USDA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Agriculture USDA filed Critical US Department of Agriculture USDA
Priority to US06/049,019 priority Critical patent/US4272398A/en
Application granted granted Critical
Publication of US4272398A publication Critical patent/US4272398A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B29WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29CSHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C67/00Shaping techniques not covered by groups B29C39/00 - B29C65/00, B29C70/00 or B29C73/00
    • B29C67/24Shaping techniques not covered by groups B29C39/00 - B29C65/00, B29C70/00 or B29C73/00 characterised by the choice of material
    • B29C67/247Moulding polymers or prepolymers containing ingredients in a frangible packaging, e.g. microcapsules
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N25/00Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
    • A01N25/26Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests in coated particulate form
    • A01N25/28Microcapsules or nanocapsules
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J13/00Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
    • B01J13/02Making microcapsules or microballoons
    • B01J13/06Making microcapsules or microballoons by phase separation
    • B01J13/12Making microcapsules or microballoons by phase separation removing solvent from the wall-forming material solution
    • B01J13/125Making microcapsules or microballoons by phase separation removing solvent from the wall-forming material solution by evaporation of the solvent
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B29WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29CSHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C67/00Shaping techniques not covered by groups B29C39/00 - B29C65/00, B29C70/00 or B29C73/00
    • B29C67/0037Forming articles from a moulding composition enclosed in a deformable bag
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B29WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29KINDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
    • B29K2995/00Properties of moulding materials, reinforcements, fillers, preformed parts or moulds
    • B29K2995/0037Other properties
    • B29K2995/0056Biocompatible, e.g. biopolymers or bioelastomers
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B29WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29KINDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
    • B29K2995/00Properties of moulding materials, reinforcements, fillers, preformed parts or moulds
    • B29K2995/0037Other properties
    • B29K2995/0059Degradable
    • B29K2995/006Bio-degradable, e.g. bioabsorbable, bioresorbable or bioerodible
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00Stock material or miscellaneous articles
    • Y10T428/29Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2989Microcapsule with solid core [includes liposome]

Definitions

  • This invention relates to a microencapsulation technique and more specifically to a method of encapsulating pesticides and insect growth regulators.
  • An object of this invention is to provide a means of encapsulating organically soluble pesticides and insect growth regulators and other organic compounds or mixtures of compounds in a biodegradable polymer such as polylactic acid and copolymers of lactic and glycolic acids.
  • Another object is to provide a means of encapsulating organically soluble pesticides and other substances in a biodegradable polymer so that the encapsulated material is plasticized in the polymer thereby providing a product having only one phase.
  • a further object is to provide a means of encapsulating organically soluble pesticides and other substances so that the product will provide a uniform release of the encapsulated substance.
  • a still further object is to provide a means of encapsulating organically soluble pesticides and other substances that will yield a product which will not prematurely release the encapsulated substance if the capsule is ruptured.
  • Still another object is to provide a microencapsulation technique that can be used to encapsulate any organic compound or mixture of organic compounds or other substance that is soluble in an organic solvent.
  • the above objects are accomplished by a method wherein the pesticide, insect growth regulator or other substance to be encapsulated and a biodegradable polymer are dissolved in a suitable solvent and the solution dispersed in an aqueous medium and stirred until the solvent evaporates and a matrix or solid solution of the pesticides or other substance is formed in the biodegradable polymer.
  • the product is the encapsulated substance plasticized in the polymer.
  • Microencapsulation is a very valuable tool and finds uses in a wide variety of industrial applications. It can be used, inter alia, to keep materials from volatilizing, to protect against oxidation, and to mask an unpleasant odor or taste.
  • one of the more interesting uses of microencapsulation is that of providing a means of slowly releasing the encapsulated material over a prolonged period of time.
  • particles of the material to be encapsulated are coated with the encapsulating material by spray or air suspension techniques or particles of the material are dispersed throughout a solution of the coating material.
  • I While searching for a simple procedure to encapsulate organic compounds or mixtures of organic compounds for pesticidal and other uses, I discovered that I could encapsulate the compound, that is, the active material, by dissolving the compound and a biodegradable polymer in a suitable solvent, dispersing the solution of active material and polymer in an aqueous medium, and stirring the dispersion until the solvent evaporated. In this manner I formed a matrix or solid solution of the active material in the biodegradable polymer, that is, the active material was plasticized in the polymer, thereby providing a one-phase product. This is in contrast to encapsulated materials in general use which are two-phase and consist of a core and shell.
  • the active material In the event of a rupture or cut or some other penetration of a two-phase capsule the active material would be rapidly released. This does not occur when the capsule is one-phase.
  • the aqueous medium consisted of water and a small amount of an anionic surfactant to help maintain the dispersion.
  • the invention is exemplified in the following examples by the microencapsulation of the pesticides famphur (O-[p-dimethylsulfomoyl phenyl]O, O-dimethyl phosphorothioate) and stirofos (2-chloro-1[2,4,5-trichlorophenyl]vinyl dimethyl phosphate) in poly(lactic acid), the non-persistent insect growth regulator, methoprene [isopropyl (E,E)-11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate], and the insect growth regulator, 2-ethoxy-9(p-isopropylphenyl)-2,6-dimethylnonane.
  • the suspension was filtered by gravity through fluted filter paper of medium-fine porosity (a smooth surface, low wet strength filter that filters 98% of 8 ⁇ m particles at medium flow rate such as Whatman #2), washed copiously with water and then air dried to yield 2.40-2.88 g. of white powder containing aggregates of microparticles.
  • the process described above was repeated eight times and the products combined. All aggregates larger than 595 ⁇ were sieved out with a number 30 standard sieve. The remaining aggregates (7.53 g.) were stirred with 600 ml. hexane for five minutes, filtered through fluted filter paper (described above), washed with 150 ml. hexane, and air dried to yield 4.93 g.
  • Example 1 0.57 g. poly (d, l-lactic acid) and 2.25 g. stirofos were dissolved in 40 ml. methylene chloride and processed as described in Example 1 to give 1.99 gm. of white powder. As in Example 1, aggregates larger than 595 ⁇ were sieved out to give 1.12 gm. of material which was washed, air dried and sized as in Example 1 to give samples 4-6 having particle size ranges the same as Examples 1-3, respectively. Sample 6 contained 42.6% active material. The amount of active material in Examples 4-5 was not determined.
  • Example 1 1.50 g. poly (L(+)-lactic acid) and 1.50 g. stirofos were dissolved in 40 ml. methylene chloride and processed as described in Example 1 to give 2.42 g. of white powder. As in Example 1, aggregates larger than 595 ⁇ were sieved out to give 0.98 g. of material which was washed, air dried and sized as in Example 1 to obtain samples 7-9 having particle size ranges the same as Examples 1-3, respectively. Sample 9 contained 47.4% active material. The amount of active material in Examples 7 and 8 was not determined.
  • Example 1 Example 1
  • Example 1 Example 1
  • All aggregates of microparticles larger than 595 ⁇ were sieved out with a number 30 standard sieve.
  • the remaining aggregates (13.92 g.) were sized as in Example 1 to yield three samples, 10-12, with the same ranges of particle sizes as samples 1-3, respectively.
  • Samples 11 and 12 contained 25.5% and 25.7% active material, respectively. The amount of active material in Sample 10 was not determined.
  • Example 4 2.0 g. poly (L(+)-lactic acid) and 1.0 g. famphur were dissolved in 45 ml. methylene chloride and processed as described in Example 4 to yield 2.0 g. of white powder. As in Example 4, aggregates larger than 595 ⁇ were sieved out. The remaining particles were sized as in Example 4 to yield three samples, 13-15, with the same ranges of particle sizes as Samples 10-12, respectively. Samples 14 and 15 contained 33.0% and 29.6% active material, respectively. The amount of active material in Sample 13 was not determined.
  • 2-ethoxy-9(p-isopropylphenyl)-2,6-dimethylnonane was encapsulated by the process described above. Individual samples of microcapsules containing 28.2% and 33.4% active material, respectively, in poly (d,l-lactic acid) were prepared.
  • 2-ethoxy-9(p-isopropylphenyl)-2,6-dimethylnonane is also effected against common cattle grub.
  • the methoprene and the 2-ethoxy-9(p-isopropylphenyl)-2,6-dimethylnonane were not formulated as suspensions in oil.
  • Individual gelatin capsules were loaded with microcapsules of the desired compound and the gelatin capsules were implanted underneath the skin, usually in the ear, of the animal being used for testing purposes.
  • the process of this invention has been exemplified with four compounds, two of which are known pesticides and two of which are known insect growth regulators, the process is applicable to other compounds and substances which are soluble in volatile organic solvents. Since the purpose of the volatile organic solvent such as methylene chloride is to solubilize the substance to be encapsulated and the biodegradable polymer prior to dispersing the solution in the aqueous medium, any volatile organic solvent in which both substances are soluble is operable and suitable in the process of this invention.
  • the volatile organic solvent such as methylene chloride

Abstract

Pesticides, insect growth regulators and other substances are encapsulated by dissolving the substance to be encapsulated and a biodegradable polymer in a suitable organic solvent, dispersing the solution in an aqueous medium and stirring until the solvent evaporates to form a matrix of the substance in the polymer.

Description

This application is a continuation-in-part of application Ser. No. 934,940, filed Aug. 17, 1978 now abandoned.
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates to a microencapsulation technique and more specifically to a method of encapsulating pesticides and insect growth regulators.
2. State of the Art
Many microencapsulation techniques are known in the art and many of them are described in "Microcapsules and Microencapsulation Techniques," M. H. Gutcho, Noyes Data Corporation, N.J., 1976. The known art which is closest to the subject invention is the following:
1. U.S. Pat. No. 3,523,906. The substance to be encapsulated is emulsified in a solution of a polymeric material in solvent and the solvent is removed by evaporation.
2. U.S. Pat. No. 3,914,402. An ophthalmic antibiotic and an ophthalmic steroid are encapsulated with polylactic acid.
3. U.S. Pat. No. 3,909,444. The material to be encapsulated is dispersed in a mixture of solvent, polymeric capsule wall material, and polyethylene, the mixture heated and then slowly cooled during the cource of which capsules are formed.
4. U.S. Pat. No. 3,557,279. Ethylcellulose, polyethylene granules and indomethacin are dispersed in cyclohexane and heated. The mixture is then allowed to cool during which the ethylcellulose lost solvent and developed into solid encapsulating walls.
SUMMARY OF THE INVENTION
An object of this invention is to provide a means of encapsulating organically soluble pesticides and insect growth regulators and other organic compounds or mixtures of compounds in a biodegradable polymer such as polylactic acid and copolymers of lactic and glycolic acids.
Another object is to provide a means of encapsulating organically soluble pesticides and other substances in a biodegradable polymer so that the encapsulated material is plasticized in the polymer thereby providing a product having only one phase.
A further object is to provide a means of encapsulating organically soluble pesticides and other substances so that the product will provide a uniform release of the encapsulated substance.
A still further object is to provide a means of encapsulating organically soluble pesticides and other substances that will yield a product which will not prematurely release the encapsulated substance if the capsule is ruptured.
Still another object is to provide a microencapsulation technique that can be used to encapsulate any organic compound or mixture of organic compounds or other substance that is soluble in an organic solvent.
According to this invention the above objects are accomplished by a method wherein the pesticide, insect growth regulator or other substance to be encapsulated and a biodegradable polymer are dissolved in a suitable solvent and the solution dispersed in an aqueous medium and stirred until the solvent evaporates and a matrix or solid solution of the pesticides or other substance is formed in the biodegradable polymer. The product is the encapsulated substance plasticized in the polymer.
DETAILED DESCRIPTION OF THE INVENTION
Microencapsulation is a very valuable tool and finds uses in a wide variety of industrial applications. It can be used, inter alia, to keep materials from volatilizing, to protect against oxidation, and to mask an unpleasant odor or taste. However, one of the more interesting uses of microencapsulation is that of providing a means of slowly releasing the encapsulated material over a prolonged period of time. Typically, particles of the material to be encapsulated are coated with the encapsulating material by spray or air suspension techniques or particles of the material are dispersed throughout a solution of the coating material.
While searching for a simple procedure to encapsulate organic compounds or mixtures of organic compounds for pesticidal and other uses, I discovered that I could encapsulate the compound, that is, the active material, by dissolving the compound and a biodegradable polymer in a suitable solvent, dispersing the solution of active material and polymer in an aqueous medium, and stirring the dispersion until the solvent evaporated. In this manner I formed a matrix or solid solution of the active material in the biodegradable polymer, that is, the active material was plasticized in the polymer, thereby providing a one-phase product. This is in contrast to encapsulated materials in general use which are two-phase and consist of a core and shell. In the event of a rupture or cut or some other penetration of a two-phase capsule the active material would be rapidly released. This does not occur when the capsule is one-phase. The aqueous medium consisted of water and a small amount of an anionic surfactant to help maintain the dispersion.
The invention is exemplified in the following examples by the microencapsulation of the pesticides famphur (O-[p-dimethylsulfomoyl phenyl]O, O-dimethyl phosphorothioate) and stirofos (2-chloro-1[2,4,5-trichlorophenyl]vinyl dimethyl phosphate) in poly(lactic acid), the non-persistent insect growth regulator, methoprene [isopropyl (E,E)-11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate], and the insect growth regulator, 2-ethoxy-9(p-isopropylphenyl)-2,6-dimethylnonane.
EXAMPLE 1
1.50 g. poly(d,l-lactic acid) and 1.50 g. stirofos were agitated in a one liter container with 40 ml. methylene chloride until complete solution of the pesticidepolymer mixture was effected. The solution was then dispersed in an aqueous medium containing 450 ml. water and 0.21 g. sodium dodecyl sulfate. The dispersion was stirred with a four-bladed stainless steel impeller (Fisher Catalog No. 14-502-5; however, any similar impeller will suffice) at about 1300-1600 r.p.m. at ambient room temperature of about 18°-22° C. for about one hour until the methylene chloride evaporated and a soapy white suspension was obtained. The suspension was filtered by gravity through fluted filter paper of medium-fine porosity (a smooth surface, low wet strength filter that filters 98% of 8 μm particles at medium flow rate such as Whatman #2), washed copiously with water and then air dried to yield 2.40-2.88 g. of white powder containing aggregates of microparticles. The process described above was repeated eight times and the products combined. All aggregates larger than 595μ were sieved out with a number 30 standard sieve. The remaining aggregates (7.53 g.) were stirred with 600 ml. hexane for five minutes, filtered through fluted filter paper (described above), washed with 150 ml. hexane, and air dried to yield 4.93 g. of white powder containing aggregated microparticles. The powder was sized with numbers 30, 50 and 80 standard sieves as described in J. Pharm. Sci. 65(6), 847, 1976, to yield three samples of aggregated microparticles. The particle size of the three samples of aggregates was as follows: 1. 295-595μ; 2. 177-295μ, and 3. <177μ. The samples contained 42.0%, 31.2%, and 23.6% active material, respectively. Examination of the aggregates by differential interference contrast microscopy showed that the aggregates were made up of generally spherical individual microcapsules having diameters ranging from about 5μ to about 162μ.
EXAMPLE 2
0.57 g. poly (d, l-lactic acid) and 2.25 g. stirofos were dissolved in 40 ml. methylene chloride and processed as described in Example 1 to give 1.99 gm. of white powder. As in Example 1, aggregates larger than 595μ were sieved out to give 1.12 gm. of material which was washed, air dried and sized as in Example 1 to give samples 4-6 having particle size ranges the same as Examples 1-3, respectively. Sample 6 contained 42.6% active material. The amount of active material in Examples 4-5 was not determined.
EXAMPLE 3
1.50 g. poly (L(+)-lactic acid) and 1.50 g. stirofos were dissolved in 40 ml. methylene chloride and processed as described in Example 1 to give 2.42 g. of white powder. As in Example 1, aggregates larger than 595μ were sieved out to give 0.98 g. of material which was washed, air dried and sized as in Example 1 to obtain samples 7-9 having particle size ranges the same as Examples 1-3, respectively. Sample 9 contained 47.4% active material. The amount of active material in Examples 7 and 8 was not determined.
EXAMPLE 4
2.20 g. poly (d,l-lactic acid) and 80 g. famphur were agitated in one liter container with 45 ml. methylene chloride until complete solution of the pesticide-polymer mixture was affected. The solution was then dispersed in an aqueous medium containing 450 ml. water and 0.21 g. sodium dodecyl sulfate. The dispersion was stirred with a four-bladed stainless steel impeller (as in Example 1) at about 1600-1800 r.p.m. at ambient room temperature of about 18°-22° C. for about 0.5 hr. The dispersion was then chilled in an ice water bath and stirred as above for about an additional 1.75 hr. until a soapy white suspension was obtained. The suspension was filtered, washed and dried as in Example 1 to yield 2.30-2.65 g. of white powder. The process was repeated six times and yields combined. All aggregates of microparticles larger than 595μ were sieved out with a number 30 standard sieve. The remaining aggregates (13.92 g.) were sized as in Example 1 to yield three samples, 10-12, with the same ranges of particle sizes as samples 1-3, respectively. Samples 11 and 12 contained 25.5% and 25.7% active material, respectively. The amount of active material in Sample 10 was not determined.
EXAMPLE 5
2.0 g. poly (L(+)-lactic acid) and 1.0 g. famphur were dissolved in 45 ml. methylene chloride and processed as described in Example 4 to yield 2.0 g. of white powder. As in Example 4, aggregates larger than 595μ were sieved out. The remaining particles were sized as in Example 4 to yield three samples, 13-15, with the same ranges of particle sizes as Samples 10-12, respectively. Samples 14 and 15 contained 33.0% and 29.6% active material, respectively. The amount of active material in Sample 13 was not determined.
EXAMPLE 6
0.90 g. poly (d,l-lactic acid) and 0.60 g. methoprene were dissolved in 25 ml. methylene chloride, the solution dispersed in 250 ml. water containing 0.11 g. sodium dodecyl sulfate, the mixture stirred for 5 minutes, then chilled in a ice-water bath while stirring was continued for a total of two hours to yield 0.94 g. of a coarse powder made up of aggregates of microcapsules containing 40.0% active materials. Two additional runs of the above process yielded microcapsules containing 33.3% and 26.5% active material, respectively, in poly (d,l-lactic acid). In addition, individual samples of microcapsules containing 33.3% and 26.5% active material, respectively, in a copolymer of 90% poly (L(+)-lactic acid) and 10% poly (glycolic acid) were prepared by the same process.
EXAMPLE 7
2-ethoxy-9(p-isopropylphenyl)-2,6-dimethylnonane was encapsulated by the process described above. Individual samples of microcapsules containing 28.2% and 33.4% active material, respectively, in poly (d,l-lactic acid) were prepared.
The various microencapsulated products obtained in Examples 1-7, above, were analyzed for percent active material by ultraviolet and infrared spectroscopic techniques as described in the Proceedings, 1977 Controlled Release Pesticide Symposium, August 22-24, 1977. As also described in the Proceedings, the microencapsulated stirofos and famphur, formulated as suspensions in oil, are useful as systemic pesticides against ticks. As described in the proceedings, 5th International Symposium on Controlled Release of Bioactive Materials, August 14-16, 1978, methoprene is an effective agent against common cattle grub. The 1977 and 1978 Proceedings are hereby considered incorporated by reference into this specification. 2-ethoxy-9(p-isopropylphenyl)-2,6-dimethylnonane is also effected against common cattle grub. The methoprene and the 2-ethoxy-9(p-isopropylphenyl)-2,6-dimethylnonane were not formulated as suspensions in oil. Individual gelatin capsules were loaded with microcapsules of the desired compound and the gelatin capsules were implanted underneath the skin, usually in the ear, of the animal being used for testing purposes.
Although the process of this invention has been exemplified with four compounds, two of which are known pesticides and two of which are known insect growth regulators, the process is applicable to other compounds and substances which are soluble in volatile organic solvents. Since the purpose of the volatile organic solvent such as methylene chloride is to solubilize the substance to be encapsulated and the biodegradable polymer prior to dispersing the solution in the aqueous medium, any volatile organic solvent in which both substances are soluble is operable and suitable in the process of this invention.

Claims (5)

I claim:
1. A process for one-phase encapsulation of organic compounds selected from the group consisting of famphur and stirofos systemic tick pesticides for oil suspension formulations and of methoprene and 2-ethoxy-9(p-isopropylphenyl)-2,6-dimethylnonane insect growth regulators comprising dissolving said compound and a biodegradable polymer selected from the group consisting of polylactic acid and copolymers of lactic and glycolic acids in methylene chloride, agitating until complete solution of the compound-polymer mixture is affected, dispersing said solution in an aqueous medium containing an anionic surfactant, and stirring said dispersion until the solvent evaporates, thereby forming a soapy white suspension of said compound in said polymer, filtering, washing, drying and sizing to white powder one-phase particles.
2. An encapsulation process for one-phase encapsulation of compounds and mixtures of compounds soluble in volatile organic solvents comprising dissolving said compound and a biodegradable polymer selected from the group consisting of polylactic acid and copolymers of lactic and glycolic acids in a suitable organic solvent, dispersing the solution in an aqueous medium containing an anionic surfactant, and stirring said dispersion until the solvent evaporates, thereby forming a soapy white suspension of said compound in said polymer, filtering, washing, drying and sizing to aggregates of one-phase particles.
3. The process of claim 2 wherein said aggregates have a particle size of from about 177μ to 595μ.
4. The process of claim 3 wherein the aggregates are formed of individual, generally spherical-shaped microcapsules, said microcapsules having diameters of from about 5μ to 162μ.
5. The process of claim 4 wherein said microcapsules contain from about 23.6 to 47.4% active material.
US06/049,019 1978-08-17 1979-06-15 Microencapsulation process Expired - Lifetime US4272398A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US06/049,019 US4272398A (en) 1978-08-17 1979-06-15 Microencapsulation process

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93494078A 1978-08-17 1978-08-17
US06/049,019 US4272398A (en) 1978-08-17 1979-06-15 Microencapsulation process

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US93494078A Continuation 1978-08-17 1978-08-17

Publications (1)

Publication Number Publication Date
US4272398A true US4272398A (en) 1981-06-09

Family

ID=26726795

Family Applications (1)

Application Number Title Priority Date Filing Date
US06/049,019 Expired - Lifetime US4272398A (en) 1978-08-17 1979-06-15 Microencapsulation process

Country Status (1)

Country Link
US (1) US4272398A (en)

Cited By (151)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4652441A (en) * 1983-11-04 1987-03-24 Takeda Chemical Industries, Ltd. Prolonged release microcapsule and its production
US4670039A (en) * 1983-03-07 1987-06-02 Metropolitan Mosquito Control District Timed release fertilizer composition and means
US4683092A (en) * 1985-07-03 1987-07-28 Damon Biotech, Inc. Capsule loading technique
EP0252897A2 (en) * 1986-07-09 1988-01-13 Monsanto Company Formulations of water-dispersible granules and process for preparation thereof
EP0252896A2 (en) * 1986-07-09 1988-01-13 Monsanto Company Water-dispersible granules and process for the preparation thereof
US4732762A (en) * 1983-03-07 1988-03-22 Metropolitan Mosquito Control District Timed release pest control composition and means
US4741858A (en) * 1987-03-02 1988-05-03 The Clorox Company Timed-release hypochlorite bleach compositions
GR880100222A (en) * 1987-04-06 1989-01-31 Cpc International Inc Control method for the plants growing
US4861627A (en) * 1987-05-01 1989-08-29 Massachusetts Institute Of Technology Preparation of multiwall polymeric microcapsules
US4898734A (en) * 1988-02-29 1990-02-06 Massachusetts Institute Of Technology Polymer composite for controlled release or membrane formation
US4986354A (en) * 1988-09-14 1991-01-22 Conoco Inc. Composition and placement process for oil field chemicals
US5019400A (en) * 1989-05-01 1991-05-28 Enzytech, Inc. Very low temperature casting of controlled release microspheres
US5066436A (en) * 1989-01-04 1991-11-19 Gist-Brocades N.V. Process for microencapsulation
DE4128910A1 (en) * 1991-08-08 1993-02-11 Cusi Lab METHOD FOR CONTINUOUS PRODUCTION OF FINE-DISTRIBUTED COLLOIDING SYSTEMS IN THE FORM OF NANOCAPSULES OR NANOPARTICLES
US5238714A (en) * 1990-10-02 1993-08-24 Board Of Regents, The University Of Texas System Efficient microcapsule preparation and method of use
WO1993025202A1 (en) * 1992-06-05 1993-12-23 Arch Development Corporation Water and uv degradable lactic acid polymers
US5300293A (en) * 1989-05-27 1994-04-05 Sumitomo Chemical Co., Ltd. Poison bait for control of noxious insects
US5360892A (en) * 1990-06-26 1994-11-01 Arch Development Corporation Water and UV degradable lactic acid polymers
US5417982A (en) * 1994-02-17 1995-05-23 Modi; Pankaj Controlled release of drugs or hormones in biodegradable polymer microspheres
EP0662097A1 (en) 1992-09-28 1995-07-12 Monsanto Company Polymer composition
US5484584A (en) * 1990-10-02 1996-01-16 Board Of Regents, The University Of Texas System Therapeutic and diagnostic use of modified polymeric microcapsules
US5569468A (en) * 1994-02-17 1996-10-29 Modi; Pankaj Vaccine delivery system for immunization, using biodegradable polymer microspheres
US5759539A (en) * 1995-06-06 1998-06-02 Georgia Research Foundation, Inc. Method for rapid enzymatic alcohol removal
US5855913A (en) * 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5874064A (en) * 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5912017A (en) * 1987-05-01 1999-06-15 Massachusetts Institute Of Technology Multiwall polymeric microspheres
WO1999032086A1 (en) * 1997-12-19 1999-07-01 Schering-Plough Animal Health Limited Solvent/surfactant insecticidal pour-on formulation
US5942253A (en) * 1995-10-12 1999-08-24 Immunex Corporation Prolonged release of GM-CSF
US5985309A (en) * 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5985354A (en) * 1995-06-07 1999-11-16 Brown University Research Foundation Preparation of multiwall polymeric microcapsules from hydrophilic polymers
US5993856A (en) * 1997-01-24 1999-11-30 Femmepharma Pharmaceutical preparations and methods for their administration
US6071497A (en) * 1995-05-15 2000-06-06 Pharmaceutical Discovery Corporation Microparticles for lung delivery comprising diketopiperazine
USRE37053E1 (en) 1996-05-24 2001-02-13 Massachusetts Institute Of Technology Particles incorporating surfactants for pulmonary drug delivery
US6262034B1 (en) 1994-03-15 2001-07-17 Neurotech S.A. Polymeric gene delivery system
US6306913B1 (en) 1993-08-31 2001-10-23 The United States Of America As Represented By The Secretary Of Agriculture Container for 4-allylanisole and analog scolytid pesticides
US20020009418A1 (en) * 2000-01-19 2002-01-24 Steiner Solomon S. Dry powder formulations of antihistamine for nasal administration
US6375872B1 (en) 1992-11-17 2002-04-23 Moore Business Forms Microencapsulated adhesive
US6395253B2 (en) 1998-04-23 2002-05-28 The Regents Of The University Of Michigan Microspheres containing condensed polyanionic bioactive agents and methods for their production
US6416778B1 (en) 1997-01-24 2002-07-09 Femmepharma Pharmaceutical preparations and methods for their regional administration
US6436443B2 (en) 1996-05-24 2002-08-20 The Penn Research Foundation, Inc. Porous particles comprising excipients for deep lung delivery
US20020147150A1 (en) * 1992-12-07 2002-10-10 Takeda Chemical Industries, Ltd. Sustained-release preparation
US20030125236A1 (en) * 2000-12-29 2003-07-03 Advenced Inhalation Research, Inc. Particles for inhalation having rapid release properties
US20030129139A1 (en) * 2001-11-20 2003-07-10 Advanced Inhalation Research, Inc. Particulate compositions for pulmonary delivery
US20030129250A1 (en) * 2001-11-20 2003-07-10 Advanced Inhalation Research Inc. Particulate compositions for improving solubility of poorly soluble agents
US20030143278A1 (en) * 2001-12-20 2003-07-31 Femmepharma, Inc. Vaginal delivery of drugs
US6652837B1 (en) 1996-05-24 2003-11-25 Massachusetts Institute Of Technology Preparation of novel particles for inhalation
US20040018243A1 (en) * 1999-08-25 2004-01-29 Advanced Inhalation Research, Inc. Modulation of release from dry powder formulations
US20040062718A1 (en) * 1996-05-24 2004-04-01 Massachusetts Institute Of Technology Particles for inhalation having sustained release properties
US20040077528A1 (en) * 1999-06-29 2004-04-22 Mannkind Corporation Purification and stabilization of peptide and protein pharmaceutical agents
WO2004033620A2 (en) 2001-11-02 2004-04-22 Insert Therapeutics, Inc. Methods and compositions for therapeutic use of rna interference
US6749835B1 (en) 1999-08-25 2004-06-15 Advanced Inhalation Research, Inc. Formulation for spray-drying large porous particles
US6817414B2 (en) 2002-09-20 2004-11-16 M-I Llc Acid coated sand for gravel pack and filter cake clean-up
US20040229813A1 (en) * 2003-01-02 2004-11-18 Femme Pharma, Inc. Pharmaceutical preparations for treatments of diseases and disorders of the breast
US20050003003A1 (en) * 1999-08-25 2005-01-06 Advanced Inhalation Research, Inc. Modulation of release from dry powder formulations
US20050025826A1 (en) * 1998-01-16 2005-02-03 Akira Saikawa Sustained release compositions, process for producing the same and utilization thereof
US20050088617A1 (en) * 2003-10-27 2005-04-28 Jen-Chuen Hsieh Method and apparatus for visual drive control
US20050153874A1 (en) * 2004-01-12 2005-07-14 Mannkind Corporation Method of reducing serum proinsulin levels in type 2 diabetics
US20050159317A1 (en) * 2002-06-25 2005-07-21 Fujitsu Limited Agricultural chemical component and decomposer for residual agricultural chemical
US6956021B1 (en) 1998-08-25 2005-10-18 Advanced Inhalation Research, Inc. Stable spray-dried protein formulations
US20050267556A1 (en) * 2004-05-28 2005-12-01 Allan Shuros Drug eluting implants to prevent cardiac apoptosis
US7048908B2 (en) 2000-12-29 2006-05-23 Advanced Inhalation Research, Inc. Particles for inhalation having sustained release properties
US7052678B2 (en) 1997-09-15 2006-05-30 Massachusetts Institute Of Technology Particles for inhalation having sustained release properties
US7070795B1 (en) 1997-06-30 2006-07-04 Monsanto Company Particles containing agricultural active ingredients
US20070020191A1 (en) * 1999-06-29 2007-01-25 Mannkind Corporation Potentiation of glucose elimination
US20070054054A1 (en) * 2002-09-20 2007-03-08 M-I L.L.C. Process for coating gravel pack sand with polymeric breaker
US20070086952A1 (en) * 2005-09-29 2007-04-19 Biodel, Inc. Rapid Acting and Prolonged Acting Inhalable Insulin Preparations
US20070203062A1 (en) * 2005-04-25 2007-08-30 Rutledge Ellis-Behnke Compositions and methods for promoting hemostasis and other physiological activities
US20070235365A1 (en) * 2004-03-12 2007-10-11 Biodel Inc. Rapid Acting Drug Delivery Compositions
WO2007120847A2 (en) 2006-04-14 2007-10-25 Massachusetts Institute Of Technology Identifying and modulating molecular pathways that mediate nervous system plasticity
US20080032934A1 (en) * 2005-04-25 2008-02-07 Clear Nano Solutions Compositions for prevention of adhesions and other barrier applications
US20080039368A1 (en) * 2006-04-12 2008-02-14 Biodel Inc. Rapid acting and long acting insulin combination formulations
US20080069865A1 (en) * 2004-01-13 2008-03-20 Southard Jeffrey L Controlled Release Cgrp Delivery Composition for Cardiovascular and Renal Indications
US20080069857A1 (en) * 2006-04-12 2008-03-20 Yoon Yeo Compositions And Methods For Inhibiting Adhesions
US20080075777A1 (en) * 2006-07-31 2008-03-27 Kennedy Michael T Apparatus and methods for preparing solid particles
US20080091233A1 (en) * 2006-04-25 2008-04-17 Massachusetts Institute Of Technology Compositions and methods for affecting movement of contaminants, bodily fluids or other entities, and/or affecting other physiological conditions
US20080090753A1 (en) * 2004-03-12 2008-04-17 Biodel, Inc. Rapid Acting Injectable Insulin Compositions
US20080153789A1 (en) * 2006-12-26 2008-06-26 Femmepharma Holding Company, Inc. Topical administration of danazol
US20080160036A1 (en) * 2006-12-27 2008-07-03 Johns Hopkins University Compositions and methods for treating inflammation and auto-immune diseases
US20080226662A1 (en) * 2000-04-28 2008-09-18 The Johns Hopkins University Dendritic cell co-stimulatory molecules
US20080227690A1 (en) * 2000-12-29 2008-09-18 Advanced Inhalation Research, Inc. Particles for inhalation having rapid release properties
US20080248999A1 (en) * 2007-04-04 2008-10-09 Biodel Inc. Amylin formulations
US20080274979A1 (en) * 2007-03-14 2008-11-06 Rutledge Ellis-Behnke Treatment of leaky or damaged tight junctions and enhancing extracellular matrix
US20090011444A1 (en) * 2006-12-27 2009-01-08 Johns Hopkins University Detection and diagnosis of inflammatory disorders
US20090023643A1 (en) * 2004-01-13 2009-01-22 Vasogenix Pharmaceuticals, Inc. Methods For Treating Acute Myocardial Infarction By Administering Calcitonin Gene Related Peptide And Compositions Containing The Same
US20090023644A1 (en) * 2004-01-13 2009-01-22 Southard Jeffery L Methods of using cgrp for cardiovascular and renal indications
US20090042292A1 (en) * 2007-07-13 2009-02-12 The Johns Hopkins University B7-DC Variants
US20090142342A1 (en) * 2006-12-27 2009-06-04 Johns Hopkins University B7-h4 receptor agonist compositions and methods for treating inflammation and auto-immune diseases
US20090175794A1 (en) * 2008-01-09 2009-07-09 Molecular Insight Pharmaceuticals, Inc. Inhibitors of carbonic anhydrase ix
US20090176317A1 (en) * 2006-04-20 2009-07-09 Mayo Foundation For Medical Education And Research Soluble B7-H1
US20090175840A1 (en) * 2008-01-04 2009-07-09 Biodel, Inc. Insulin formulations for insulin release as a function of tissue glucose levels
US20090203598A1 (en) * 2006-05-19 2009-08-13 Georgia Tech Research Corporation Abc transporter ligand
US20090215084A1 (en) * 2006-01-05 2009-08-27 Mayo Foundation For Medical Education And Research B7-h1 and b7-h4 in cancer
US20090239800A1 (en) * 2006-07-14 2009-09-24 Georgia Tech Research Corporarion CLC Channel Ligand
US20100015642A1 (en) * 2006-01-05 2010-01-21 Kwon Eugene D B7-h1 and survivin in cancer
US7678364B2 (en) 1999-08-25 2010-03-16 Alkermes, Inc. Particles for inhalation having sustained release properties
US7713929B2 (en) 2006-04-12 2010-05-11 Biodel Inc. Rapid acting and long acting insulin combination formulations
US20100178246A1 (en) * 2008-12-05 2010-07-15 Molecular Insight Pharmaceuticals, Inc. Technetium- and rhenium-bis(heteroaryl) complexes and methods of use thereof for inhibiting psma
US20100183509A1 (en) * 2008-01-09 2010-07-22 Molecular Insight Pharmaceuticals, Inc. Technetium- and rhenium-bis(heteroaryl) complexes and methods of use thereof
US20110003000A1 (en) * 2009-07-06 2011-01-06 Femmepharma Holding Company, Inc. Transvaginal Delivery of Drugs
WO2011005756A1 (en) 2009-07-06 2011-01-13 Puretech Ventures, Llc Delivery of agents targeted to microbiota niches
US20110020325A1 (en) * 2008-02-29 2011-01-27 Kwon Eugene D Methods for reducing granulomatous inflammation
US20110195068A1 (en) * 2008-08-25 2011-08-11 Solomon Langermann Pd-1 antagonists and methods of use thereof
US20110200620A1 (en) * 2004-10-06 2011-08-18 Lieping Chen B7-h1 and methods of diagnosis, prognosis, and treatment of cancer
US8039589B1 (en) 2002-10-04 2011-10-18 Mayo Foundation For Medical Education And Research B7-DC variants
US8084420B2 (en) 2005-09-29 2011-12-27 Biodel Inc. Rapid acting and long acting insulin combination formulations
WO2012058715A1 (en) 2010-11-01 2012-05-10 University Of Technology, Sydney Immune-modulating agents and uses therefor
US8211402B2 (en) 2008-12-05 2012-07-03 Molecular Insight Pharmaceuticals, Inc. CA-IX specific radiopharmaceuticals for the treatment and imaging of cancer
US8460927B2 (en) 1999-11-30 2013-06-11 Mayo Foundation For Medical Education And Research B7-H1 antibodies and method of use
US8623817B2 (en) 2008-08-11 2014-01-07 Mannkind Corporation Method of treating diabetes type 2 by administering ultrarapid acting insulin
US8709416B2 (en) 2008-08-25 2014-04-29 Amplimmune, Inc. Compositions of PD-1 antagonists and methods of use
US8785396B2 (en) 2007-10-24 2014-07-22 Mannkind Corporation Method and composition for treating migraines
US9005616B2 (en) 2009-08-31 2015-04-14 Amplimmune, Inc. Methods and compositions for the inhibition of transplant rejection
US9060927B2 (en) 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
US9120837B2 (en) 2012-01-06 2015-09-01 Molecular Insight Pharmaceuticals Metal complexes of poly(carboxyl)amine-containing ligands having an affinity for carbonic anhydrase IX
US9149547B2 (en) 2009-06-15 2015-10-06 Molecular Insight Pharmaceuticals, Inc. Process for production of heterodimers of glutamic acid
US9173836B2 (en) 2003-01-02 2015-11-03 FemmeParma Holding Company, Inc. Pharmaceutical preparations for treatments of diseases and disorders of the breast
US9192675B2 (en) 2008-06-13 2015-11-24 Mankind Corporation Dry powder inhaler and system for drug delivery
WO2015179918A1 (en) 2014-05-27 2015-12-03 The University Of Queensland Modulation of cellular stress
US9220687B2 (en) 2008-12-29 2015-12-29 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
EP2963017A1 (en) 2002-03-11 2016-01-06 Molecular Insight Pharmaceuticals, Inc. Technetium-dipyridine complexes, and methods of use thereof
US9233159B2 (en) 2011-10-24 2016-01-12 Mannkind Corporation Methods and compositions for treating pain
US9241903B2 (en) 2006-02-22 2016-01-26 Mannkind Corporation Method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent
US9283193B2 (en) 2005-09-14 2016-03-15 Mannkind Corporation Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents
US9339476B2 (en) 2013-08-22 2016-05-17 Arch Biosurgery, Inc. Implantable meshes for controlling the movement of fluids
US9346766B2 (en) 2004-08-20 2016-05-24 Mannkind Corporation Catalysis of diketopiperazine synthesis
US9364619B2 (en) 2008-06-20 2016-06-14 Mannkind Corporation Interactive apparatus and method for real-time profiling of inhalation efforts
US9364436B2 (en) 2011-06-17 2016-06-14 Mannkind Corporation High capacity diketopiperazine microparticles and methods
US9439941B2 (en) 2009-12-14 2016-09-13 The University Of Hong Kong Nano cancer barrier device (NCBD) to immobilize and inhibit the division of metastic cancer stem cells
US9630930B2 (en) 2009-06-12 2017-04-25 Mannkind Corporation Diketopiperazine microparticles with defined specific surface areas
US9662461B2 (en) 2008-06-13 2017-05-30 Mannkind Corporation Dry powder drug delivery system and methods
US9675674B2 (en) 2004-08-23 2017-06-13 Mannkind Corporation Diketopiperazine salts for drug delivery and related methods
US9700690B2 (en) 2002-03-20 2017-07-11 Mannkind Corporation Inhalation apparatus
US9706944B2 (en) 2009-11-03 2017-07-18 Mannkind Corporation Apparatus and method for simulating inhalation efforts
US9802012B2 (en) 2012-07-12 2017-10-31 Mannkind Corporation Dry powder drug delivery system and methods
US9925144B2 (en) 2013-07-18 2018-03-27 Mannkind Corporation Heat-stable dry powder pharmaceutical compositions and methods
US9983108B2 (en) 2009-03-11 2018-05-29 Mannkind Corporation Apparatus, system and method for measuring resistance of an inhaler
US10086096B2 (en) 2013-01-14 2018-10-02 Molecular Insight Pharmaceuticals, Inc. Triazine based radiopharmaceuticals and radioimaging agents
US10159644B2 (en) 2012-10-26 2018-12-25 Mannkind Corporation Inhalable vaccine compositions and methods
US10167336B2 (en) 2013-03-14 2019-01-01 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
US10259875B2 (en) 2013-10-01 2019-04-16 Mayo Foundation For Medical Education And Research Methods for treating cancer in patients with elevated levels of BIM
US10302653B2 (en) 2014-05-22 2019-05-28 Mayo Foundation For Medical Education And Research Distinguishing antagonistic and agonistic anti B7-H1 antibodies
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
US10342938B2 (en) 2008-06-13 2019-07-09 Mannkind Corporation Dry powder drug delivery system
US10421729B2 (en) 2013-03-15 2019-09-24 Mannkind Corporation Microcrystalline diketopiperazine compositions and methods
WO2019236669A1 (en) * 2018-06-08 2019-12-12 The United States Of America, As Represented By The Secretary Of Agriculture Compositions containing microencapsulated organic compounds
US10517875B2 (en) 2014-07-23 2019-12-31 Mayo Foundation for Medical Engineering and Research Targeting DNA-PKcs and B7-H1 to treat cancer
EP3590503A1 (en) 2006-10-12 2020-01-08 The University of Queensland Compositions and methods for modulating immune responses
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
US10625034B2 (en) 2011-04-01 2020-04-21 Mannkind Corporation Blister package for pharmaceutical cartridges
US10875923B2 (en) 2015-10-30 2020-12-29 Mayo Foundation For Medical Education And Research Antibodies to B7-H1
US11446127B2 (en) 2013-08-05 2022-09-20 Mannkind Corporation Insufflation apparatus and methods

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3523906A (en) * 1962-07-11 1970-08-11 Gevaert Photo Prod Nv Process for encapsulating water and compounds in aqueous phase by evaporation
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3887699A (en) * 1969-03-24 1975-06-03 Seymour Yolles Biodegradable polymeric article for dispensing drugs
US3976071A (en) * 1974-01-07 1976-08-24 Dynatech Corporation Methods of improving control of release rates and products useful in same

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3523906A (en) * 1962-07-11 1970-08-11 Gevaert Photo Prod Nv Process for encapsulating water and compounds in aqueous phase by evaporation
US3887699A (en) * 1969-03-24 1975-06-03 Seymour Yolles Biodegradable polymeric article for dispensing drugs
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3976071A (en) * 1974-01-07 1976-08-24 Dynatech Corporation Methods of improving control of release rates and products useful in same

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Controlled Release Polymeric Formulations, ACS Symposium Series 33, Amer. Chem. Soc., 1976, Chapter 8. *
Proceedings, 1977 Controlled Release Pesticide Symposium, Aug. 22-24, 1977, Oregon State Univ. *
Proceedings, 5th Internat'l Symposium on Controlled Release of Bioactive Materials, Aug. 14-16, 1978. *
Sinclair, Environmental Sci. Technol. 1973, 7 (10) 955-956. *

Cited By (292)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4732762A (en) * 1983-03-07 1988-03-22 Metropolitan Mosquito Control District Timed release pest control composition and means
US4670039A (en) * 1983-03-07 1987-06-02 Metropolitan Mosquito Control District Timed release fertilizer composition and means
US4711782A (en) * 1983-11-04 1987-12-08 Takeda Chemical Industries, Ltd. Prolonged release microcapsules and their production
US5631020A (en) * 1983-11-04 1997-05-20 Takeda Chemical Industries, Ltd. Method for producing microcapsule
US4652441A (en) * 1983-11-04 1987-03-24 Takeda Chemical Industries, Ltd. Prolonged release microcapsule and its production
US5476663A (en) * 1983-11-04 1995-12-19 Takeda Chemical Industries, Ltd. Prolonged release microcapsule
US5061492A (en) * 1983-11-04 1991-10-29 Takeda Chemical Industries, Ltd. Prolonged release microcapsule of a water-soluble drug
US5631021A (en) * 1983-11-04 1997-05-20 Takeda Chemical Industries, Ltd. Method for producing microcapsule
US4917893A (en) * 1983-11-04 1990-04-17 Takeda Chemical Industries, Ltd. Prolonged release microcapsules
US4683092A (en) * 1985-07-03 1987-07-28 Damon Biotech, Inc. Capsule loading technique
EP0252897A2 (en) * 1986-07-09 1988-01-13 Monsanto Company Formulations of water-dispersible granules and process for preparation thereof
EP0252896A2 (en) * 1986-07-09 1988-01-13 Monsanto Company Water-dispersible granules and process for the preparation thereof
EP0252897A3 (en) * 1986-07-09 1990-05-16 Monsanto Company Formulations of water-dispersible granules and process for preparation thereof
EP0252896A3 (en) * 1986-07-09 1990-05-23 Monsanto Company Water-dispersible granules and process for the preparation thereof
US4741858A (en) * 1987-03-02 1988-05-03 The Clorox Company Timed-release hypochlorite bleach compositions
EP0355117A4 (en) * 1987-04-06 1990-06-26 Cpc International Inc Method for regulating plant growth.
EP0355117A1 (en) * 1987-04-06 1990-02-28 Cpc International Inc Method for regulating plant growth.
USRE35320E (en) * 1987-04-06 1996-08-27 Cpc International Inc. Method for regulating plant growth
GR880100222A (en) * 1987-04-06 1989-01-31 Cpc International Inc Control method for the plants growing
US6511749B1 (en) 1987-05-01 2003-01-28 Brown University Research Foundation Preparation of multiwall polymeric microcapsules from hydrophilic polymers
US5912017A (en) * 1987-05-01 1999-06-15 Massachusetts Institute Of Technology Multiwall polymeric microspheres
US4861627A (en) * 1987-05-01 1989-08-29 Massachusetts Institute Of Technology Preparation of multiwall polymeric microcapsules
US4898734A (en) * 1988-02-29 1990-02-06 Massachusetts Institute Of Technology Polymer composite for controlled release or membrane formation
US4986354A (en) * 1988-09-14 1991-01-22 Conoco Inc. Composition and placement process for oil field chemicals
US5066436A (en) * 1989-01-04 1991-11-19 Gist-Brocades N.V. Process for microencapsulation
US5019400A (en) * 1989-05-01 1991-05-28 Enzytech, Inc. Very low temperature casting of controlled release microspheres
US5300293A (en) * 1989-05-27 1994-04-05 Sumitomo Chemical Co., Ltd. Poison bait for control of noxious insects
US5360892A (en) * 1990-06-26 1994-11-01 Arch Development Corporation Water and UV degradable lactic acid polymers
US5238714A (en) * 1990-10-02 1993-08-24 Board Of Regents, The University Of Texas System Efficient microcapsule preparation and method of use
US5484584A (en) * 1990-10-02 1996-01-16 Board Of Regents, The University Of Texas System Therapeutic and diagnostic use of modified polymeric microcapsules
DE4128910A1 (en) * 1991-08-08 1993-02-11 Cusi Lab METHOD FOR CONTINUOUS PRODUCTION OF FINE-DISTRIBUTED COLLOIDING SYSTEMS IN THE FORM OF NANOCAPSULES OR NANOPARTICLES
WO1993025202A1 (en) * 1992-06-05 1993-12-23 Arch Development Corporation Water and uv degradable lactic acid polymers
EP0662097A1 (en) 1992-09-28 1995-07-12 Monsanto Company Polymer composition
EP0662097B1 (en) * 1992-09-28 2002-05-22 Monsanto Company Polymer composition
US6375872B1 (en) 1992-11-17 2002-04-23 Moore Business Forms Microencapsulated adhesive
US7048947B2 (en) 1992-12-07 2006-05-23 Takeda Pharmaceutical Company Limited Sustained-release preparation
US20020173467A1 (en) * 1992-12-07 2002-11-21 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6528093B1 (en) 1992-12-07 2003-03-04 Takeda Chemical Industries, Ltd. Sustained-release preparation
US20020147150A1 (en) * 1992-12-07 2002-10-10 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6306913B1 (en) 1993-08-31 2001-10-23 The United States Of America As Represented By The Secretary Of Agriculture Container for 4-allylanisole and analog scolytid pesticides
US5569468A (en) * 1994-02-17 1996-10-29 Modi; Pankaj Vaccine delivery system for immunization, using biodegradable polymer microspheres
US5417982A (en) * 1994-02-17 1995-05-23 Modi; Pankaj Controlled release of drugs or hormones in biodegradable polymer microspheres
US6620617B2 (en) 1994-03-15 2003-09-16 Brown University Research Foundation Polymeric gene delivery system
US6475779B2 (en) 1994-03-15 2002-11-05 Neurotech S.A. Polymeric gene delivery
US6262034B1 (en) 1994-03-15 2001-07-17 Neurotech S.A. Polymeric gene delivery system
US20040126884A1 (en) * 1994-03-15 2004-07-01 Edith Mathiowitz Polymeric gene delivery system
US20040096403A1 (en) * 1995-05-15 2004-05-20 Mannkind Corporation Method for drug delivery to the pulmonary system
US6071497A (en) * 1995-05-15 2000-06-06 Pharmaceutical Discovery Corporation Microparticles for lung delivery comprising diketopiperazine
US8394414B2 (en) 1995-05-15 2013-03-12 Mannkind Corporation Method for drug delivery to the pulmonary system
US5759539A (en) * 1995-06-06 1998-06-02 Georgia Research Foundation, Inc. Method for rapid enzymatic alcohol removal
US6528035B1 (en) 1995-06-07 2003-03-04 Brown University Research Foundation Multiwall polymeric microcapsules from hydrophilic polymers
US5985354A (en) * 1995-06-07 1999-11-16 Brown University Research Foundation Preparation of multiwall polymeric microcapsules from hydrophilic polymers
US5942253A (en) * 1995-10-12 1999-08-24 Immunex Corporation Prolonged release of GM-CSF
US6274175B1 (en) 1995-10-12 2001-08-14 Immunex Corporation Prolonged release of GM-CSF
US6120807A (en) * 1995-10-12 2000-09-19 Immunex Corporation Prolonged release of GM-CSF
US6136295A (en) * 1996-05-24 2000-10-24 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5874064A (en) * 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US6447753B2 (en) 1996-05-24 2002-09-10 The Penn Research Foundation, Inc. Porous particles for deep lung delivery
US6436443B2 (en) 1996-05-24 2002-08-20 The Penn Research Foundation, Inc. Porous particles comprising excipients for deep lung delivery
US20050158249A1 (en) * 1996-05-24 2005-07-21 Edwards David A. Aerodynamically light particles for pulmonary drug delivery
US6399102B1 (en) 1996-05-24 2002-06-04 The Penn State Research Foundation Aerodynamically light particles for pulmonary drug delivery
US20040191186A1 (en) * 1996-05-24 2004-09-30 Massachusetts Institute Of Technology Porous particles comprising excipients for deep lung delivery
USRE37053E1 (en) 1996-05-24 2001-02-13 Massachusetts Institute Of Technology Particles incorporating surfactants for pulmonary drug delivery
US6942868B2 (en) 1996-05-24 2005-09-13 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US6447752B2 (en) 1996-05-24 2002-09-10 The Penn State Research Foundation Amorphous porous particles for deep lung delivery
US7628977B2 (en) 1996-05-24 2009-12-08 Massachusetts Institute Of Technology Particles for inhalation having sustained release properties
US6740310B2 (en) 1996-05-24 2004-05-25 Massachusetts Institute Of Technology Porous particles comprising excipients for deep lung delivery
US20080253971A9 (en) * 1996-05-24 2008-10-16 Massachusetts Institute Of Technology Particles for inhalation having sustained release properties
US5985309A (en) * 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US6635283B2 (en) 1996-05-24 2003-10-21 Penn State Res Found Aerodynamically light particles for pulmonary drug delivery
US6652837B1 (en) 1996-05-24 2003-11-25 Massachusetts Institute Of Technology Preparation of novel particles for inhalation
US20040062718A1 (en) * 1996-05-24 2004-04-01 Massachusetts Institute Of Technology Particles for inhalation having sustained release properties
US7435408B2 (en) 1996-05-24 2008-10-14 Massachusetts Institute Of Technology Porous particles comprising excipients for deep lung delivery
US20040047811A1 (en) * 1996-05-24 2004-03-11 The Penn State Research Foundation Aerodynamically light particles for pulmonary drug delivery
US5855913A (en) * 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US6416778B1 (en) 1997-01-24 2002-07-09 Femmepharma Pharmaceutical preparations and methods for their regional administration
US6652874B2 (en) 1997-01-24 2003-11-25 Femmepharma Pharmaceutical preparations and methods for their regional administration
US5993856A (en) * 1997-01-24 1999-11-30 Femmepharma Pharmaceutical preparations and methods for their administration
US7070795B1 (en) 1997-06-30 2006-07-04 Monsanto Company Particles containing agricultural active ingredients
US7452546B2 (en) 1997-06-30 2008-11-18 Monsanto Technology Llc Particles containing agricultural active ingredients
US20060193882A1 (en) * 1997-06-30 2006-08-31 Monsanto Technology, L.L.C. Particles containing agricultural active ingredients
US7052678B2 (en) 1997-09-15 2006-05-30 Massachusetts Institute Of Technology Particles for inhalation having sustained release properties
US20070014738A1 (en) * 1997-09-15 2007-01-18 Edwards David A Particles for inhalation having sustained release properties
WO1999032086A1 (en) * 1997-12-19 1999-07-01 Schering-Plough Animal Health Limited Solvent/surfactant insecticidal pour-on formulation
US20050025826A1 (en) * 1998-01-16 2005-02-03 Akira Saikawa Sustained release compositions, process for producing the same and utilization thereof
US7388032B2 (en) * 1998-01-16 2008-06-17 Takeda Pharmaceutical Company Limited Sustained release compositions, process for producing the same and utilization thereof
US6395253B2 (en) 1998-04-23 2002-05-28 The Regents Of The University Of Michigan Microspheres containing condensed polyanionic bioactive agents and methods for their production
US20060002996A1 (en) * 1998-08-25 2006-01-05 Edwards David A Stable spray-dried protein formulations
US6956021B1 (en) 1998-08-25 2005-10-18 Advanced Inhalation Research, Inc. Stable spray-dried protein formulations
US7648960B2 (en) 1999-06-29 2010-01-19 Mannkind Corporation Method for delivery of monomeric or dimeric insulin complexed to diketopiperazine microparticles
US20070020191A1 (en) * 1999-06-29 2007-01-25 Mannkind Corporation Potentiation of glucose elimination
US8889099B2 (en) 1999-06-29 2014-11-18 Mannkind Corporation Methods and compositions for delivering peptides
US20040077528A1 (en) * 1999-06-29 2004-04-22 Mannkind Corporation Purification and stabilization of peptide and protein pharmaceutical agents
US9801925B2 (en) 1999-06-29 2017-10-31 Mannkind Corporation Potentiation of glucose elimination
US20100086609A1 (en) * 1999-06-29 2010-04-08 Mannkind Corporation Methods and Compositions for Delivering Peptides
US8389470B2 (en) 1999-06-29 2013-03-05 Mannkind Corporation Methods and compositions for delivering peptides
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
US20110105391A1 (en) * 1999-06-29 2011-05-05 Mannkind Corporation Methods and Compositions for Delivering Peptides
US7943178B2 (en) 1999-06-29 2011-05-17 Mannkind Corporation Methods and compositions for delivering peptides
US7678364B2 (en) 1999-08-25 2010-03-16 Alkermes, Inc. Particles for inhalation having sustained release properties
US20040018243A1 (en) * 1999-08-25 2004-01-29 Advanced Inhalation Research, Inc. Modulation of release from dry powder formulations
US20050003003A1 (en) * 1999-08-25 2005-01-06 Advanced Inhalation Research, Inc. Modulation of release from dry powder formulations
US6749835B1 (en) 1999-08-25 2004-06-15 Advanced Inhalation Research, Inc. Formulation for spray-drying large porous particles
US8460927B2 (en) 1999-11-30 2013-06-11 Mayo Foundation For Medical Education And Research B7-H1 antibodies and method of use
US7833549B2 (en) 2000-01-19 2010-11-16 Mannkind Corporation Dry powder formulations of antihistamine for nasal administration
US20020009418A1 (en) * 2000-01-19 2002-01-24 Steiner Solomon S. Dry powder formulations of antihistamine for nasal administration
US20080038358A1 (en) * 2000-01-19 2008-02-14 Mannkind Corporation Dry powder formulations of antihistamine for nasal administration
US7833550B2 (en) 2000-01-19 2010-11-16 Mannkind Corporation Dry powder formulations of antihistamine for nasal administration
US20080226662A1 (en) * 2000-04-28 2008-09-18 The Johns Hopkins University Dendritic cell co-stimulatory molecules
US8053558B2 (en) 2000-04-28 2011-11-08 The Johns Hopkins University Dendritic cell co-stimulatory molecules
US8053414B2 (en) 2000-04-28 2011-11-08 The Johns Hopkins University Methods of using B7-DC molecules to induce or enhance an immune response
US9370565B2 (en) 2000-04-28 2016-06-21 The Johns Hopkins University Dendritic cell co-stimulatory molecules
US20080241175A1 (en) * 2000-04-28 2008-10-02 The Johns Hopkins University Dendritic Cell Co-Stimulatory Molecules
US7048908B2 (en) 2000-12-29 2006-05-23 Advanced Inhalation Research, Inc. Particles for inhalation having sustained release properties
US20030125236A1 (en) * 2000-12-29 2003-07-03 Advenced Inhalation Research, Inc. Particles for inhalation having rapid release properties
US20080039366A1 (en) * 2000-12-29 2008-02-14 Advanced Inhalation Research Particles for inhalation having sustained release properties
US20080227690A1 (en) * 2000-12-29 2008-09-18 Advanced Inhalation Research, Inc. Particles for inhalation having rapid release properties
EP2325193A2 (en) 2001-11-02 2011-05-25 Insert Therapeutics, Inc. Methods and compositions for therapeutic use of RNA interference
WO2004033620A2 (en) 2001-11-02 2004-04-22 Insert Therapeutics, Inc. Methods and compositions for therapeutic use of rna interference
US7384649B2 (en) 2001-11-20 2008-06-10 Advanced Inhalation Research, Inc. Particulate compositions for pulmonary delivery
US20030129250A1 (en) * 2001-11-20 2003-07-10 Advanced Inhalation Research Inc. Particulate compositions for improving solubility of poorly soluble agents
US20070104657A1 (en) * 2001-11-20 2007-05-10 Batycky Richard P Particulate compositions for pulmonary delivery
US20030129139A1 (en) * 2001-11-20 2003-07-10 Advanced Inhalation Research, Inc. Particulate compositions for pulmonary delivery
US7182961B2 (en) 2001-11-20 2007-02-27 Advanced Inhalation Research, Inc. Particulate compositions for pulmonary delivery
US8226972B2 (en) 2001-12-20 2012-07-24 Femmepharma Holding Company, Inc. Vaginal delivery of drugs
US20030143278A1 (en) * 2001-12-20 2003-07-31 Femmepharma, Inc. Vaginal delivery of drugs
EP2963017A1 (en) 2002-03-11 2016-01-06 Molecular Insight Pharmaceuticals, Inc. Technetium-dipyridine complexes, and methods of use thereof
US9700690B2 (en) 2002-03-20 2017-07-11 Mannkind Corporation Inhalation apparatus
US8030245B2 (en) * 2002-06-25 2011-10-04 Fujitsu Limited Agricultural chemical component and decomposer for residual agricultural chemical
US20050159317A1 (en) * 2002-06-25 2005-07-21 Fujitsu Limited Agricultural chemical component and decomposer for residual agricultural chemical
US6817414B2 (en) 2002-09-20 2004-11-16 M-I Llc Acid coated sand for gravel pack and filter cake clean-up
US20070054054A1 (en) * 2002-09-20 2007-03-08 M-I L.L.C. Process for coating gravel pack sand with polymeric breaker
US7972997B2 (en) 2002-09-20 2011-07-05 M-I L.L.C. Process for coating gravel pack sand with polymeric breaker
US8273864B2 (en) 2002-10-04 2012-09-25 Mayo Foundation For Medical Education And Research Nucleic acid molecules encoding B7-DC variants
US8039589B1 (en) 2002-10-04 2011-10-18 Mayo Foundation For Medical Education And Research B7-DC variants
US9173836B2 (en) 2003-01-02 2015-11-03 FemmeParma Holding Company, Inc. Pharmaceutical preparations for treatments of diseases and disorders of the breast
US7812010B2 (en) 2003-01-02 2010-10-12 Femmepharma, Inc. Pharmaceutical preparations for treatments of diseases and disorders of the breast
US20040229813A1 (en) * 2003-01-02 2004-11-18 Femme Pharma, Inc. Pharmaceutical preparations for treatments of diseases and disorders of the breast
US20050088617A1 (en) * 2003-10-27 2005-04-28 Jen-Chuen Hsieh Method and apparatus for visual drive control
US20050153874A1 (en) * 2004-01-12 2005-07-14 Mannkind Corporation Method of reducing serum proinsulin levels in type 2 diabetics
US20090023644A1 (en) * 2004-01-13 2009-01-22 Southard Jeffery L Methods of using cgrp for cardiovascular and renal indications
US20090023643A1 (en) * 2004-01-13 2009-01-22 Vasogenix Pharmaceuticals, Inc. Methods For Treating Acute Myocardial Infarction By Administering Calcitonin Gene Related Peptide And Compositions Containing The Same
US7976847B2 (en) 2004-01-13 2011-07-12 Vasogenix Pharmaceuticals, Inc. Controlled release CGRP delivery composition for cardiovascular and renal indications
US20080069865A1 (en) * 2004-01-13 2008-03-20 Southard Jeffrey L Controlled Release Cgrp Delivery Composition for Cardiovascular and Renal Indications
US20090192075A1 (en) * 2004-03-12 2009-07-30 Biodel Inc. Amylin Formulations
US20080090753A1 (en) * 2004-03-12 2008-04-17 Biodel, Inc. Rapid Acting Injectable Insulin Compositions
US20070235365A1 (en) * 2004-03-12 2007-10-11 Biodel Inc. Rapid Acting Drug Delivery Compositions
US8933023B2 (en) 2004-03-12 2015-01-13 Biodel Inc. Rapid acting injectable insulin compositions
US20050267556A1 (en) * 2004-05-28 2005-12-01 Allan Shuros Drug eluting implants to prevent cardiac apoptosis
US9796688B2 (en) 2004-08-20 2017-10-24 Mannkind Corporation Catalysis of diketopiperazine synthesis
US9346766B2 (en) 2004-08-20 2016-05-24 Mannkind Corporation Catalysis of diketopiperazine synthesis
US9675674B2 (en) 2004-08-23 2017-06-13 Mannkind Corporation Diketopiperazine salts for drug delivery and related methods
US10130685B2 (en) 2004-08-23 2018-11-20 Mannkind Corporation Diketopiperazine salts for drug delivery and related methods
US8747833B2 (en) 2004-10-06 2014-06-10 Mayo Foundation For Medical Education And Research B7-H1 and methods of diagnosis, prognosis, and treatment of cancer
US20110200620A1 (en) * 2004-10-06 2011-08-18 Lieping Chen B7-h1 and methods of diagnosis, prognosis, and treatment of cancer
US11242387B2 (en) 2004-10-06 2022-02-08 Mayo Foundation For Medical Education And Research Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target
US9803015B2 (en) 2004-10-06 2017-10-31 Mayo Foundation For Medical Education And Research Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target
US20110183901A1 (en) * 2005-03-31 2011-07-28 Mannkind Corporation Superior Control of Blood Glucose in Diabetes Treatment
US20070203062A1 (en) * 2005-04-25 2007-08-30 Rutledge Ellis-Behnke Compositions and methods for promoting hemostasis and other physiological activities
US20080032934A1 (en) * 2005-04-25 2008-02-07 Clear Nano Solutions Compositions for prevention of adhesions and other barrier applications
US20090111734A1 (en) * 2005-04-25 2009-04-30 Massachusetts Institute Of Technology Compositions and methods for promoting hemostasis and other physiological activities
EP2283851A2 (en) 2005-04-25 2011-02-16 Massachusetts Institute of Technology Compositions and methods for promoting hemostasis and other physiological activities
US9789157B2 (en) 2005-04-25 2017-10-17 Arch Biosurgery, Inc. Compositions for prevention of adhesions and other barrier applications
US9162005B2 (en) 2005-04-25 2015-10-20 Arch Biosurgery, Inc. Compositions for prevention of adhesions and other barrier applications
US11839694B2 (en) 2005-04-25 2023-12-12 Massachusetts Institute Of Technology Compositions and methods for promoting hemostasis and other physiological activities
US9364513B2 (en) 2005-04-25 2016-06-14 Maasachusetts Institute of Technology Compositions and methods for promoting hemostasis and other physiological activities
US9327010B2 (en) 2005-04-25 2016-05-03 Massachusetts Institute Of Technology Compositions and methods for promoting hemostasis and other physiological activities
US9717689B2 (en) 2005-09-14 2017-08-01 Mannkind Corporation Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents
US9283193B2 (en) 2005-09-14 2016-03-15 Mannkind Corporation Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents
US10143655B2 (en) 2005-09-14 2018-12-04 Mannkind Corporation Method of drug formulation
US9446001B2 (en) 2005-09-14 2016-09-20 Mannkind Corporation Increasing drug affinity for crystalline microparticle surfaces
US8084420B2 (en) 2005-09-29 2011-12-27 Biodel Inc. Rapid acting and long acting insulin combination formulations
US20070086952A1 (en) * 2005-09-29 2007-04-19 Biodel, Inc. Rapid Acting and Prolonged Acting Inhalable Insulin Preparations
US20100015642A1 (en) * 2006-01-05 2010-01-21 Kwon Eugene D B7-h1 and survivin in cancer
US20090215084A1 (en) * 2006-01-05 2009-08-27 Mayo Foundation For Medical Education And Research B7-h1 and b7-h4 in cancer
US9241903B2 (en) 2006-02-22 2016-01-26 Mannkind Corporation Method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent
US10130581B2 (en) 2006-02-22 2018-11-20 Mannkind Corporation Method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent
US7713929B2 (en) 2006-04-12 2010-05-11 Biodel Inc. Rapid acting and long acting insulin combination formulations
US7718609B2 (en) 2006-04-12 2010-05-18 Biodel Inc. Rapid acting and long acting insulin combination formulations
US20080039368A1 (en) * 2006-04-12 2008-02-14 Biodel Inc. Rapid acting and long acting insulin combination formulations
US20080069857A1 (en) * 2006-04-12 2008-03-20 Yoon Yeo Compositions And Methods For Inhibiting Adhesions
WO2007120847A2 (en) 2006-04-14 2007-10-25 Massachusetts Institute Of Technology Identifying and modulating molecular pathways that mediate nervous system plasticity
US8969295B2 (en) 2006-04-14 2015-03-03 Massachusetts Institute Of Technology Identifying and modulating molecular pathways that mediate nervous system plasticity
US20090297573A1 (en) * 2006-04-14 2009-12-03 Massachusetts Institute Of Technology Identifying and Modulating Molecular Pathways that Mediate Nervous System Plasticity
US20090176317A1 (en) * 2006-04-20 2009-07-09 Mayo Foundation For Medical Education And Research Soluble B7-H1
US10682386B2 (en) 2006-04-25 2020-06-16 Arch Biosurgery, Inc. Compositions for prevention of adhesions and other barrier applications
US9084837B2 (en) 2006-04-25 2015-07-21 Massachusetts Institute Of Technology Compositions and methods for affecting movement of contaminants, bodily fluids or other entities, and/or affecting other physiological conditions
US20080091233A1 (en) * 2006-04-25 2008-04-17 Massachusetts Institute Of Technology Compositions and methods for affecting movement of contaminants, bodily fluids or other entities, and/or affecting other physiological conditions
US9511113B2 (en) 2006-04-25 2016-12-06 Massachusetts Institute Of Technology Compositions and methods for affecting movement of contaminants, bodily fluids or other entities, and/or affecting other physiological conditions
US10137166B2 (en) 2006-04-25 2018-11-27 Massachusetts Institute Of Technology Compositions and methods for affecting movement of contaminants, bodily fluids or other entities, and/or affecting other physiological conditions
US20090203598A1 (en) * 2006-05-19 2009-08-13 Georgia Tech Research Corporation Abc transporter ligand
US8106013B2 (en) 2006-05-19 2012-01-31 Georgia Tech Research Corporation ABC transporter ligand GATX1
WO2007147072A1 (en) 2006-06-14 2007-12-21 M-I Llc Process for coating gravel pack sand with polymeric breaker
US20090239800A1 (en) * 2006-07-14 2009-09-24 Georgia Tech Research Corporarion CLC Channel Ligand
US8324158B2 (en) 2006-07-14 2012-12-04 Georgia Tech Research Corporation Methods for inhibiting CLC-2 channel with GATX2
US20080075777A1 (en) * 2006-07-31 2008-03-27 Kennedy Michael T Apparatus and methods for preparing solid particles
EP3590503A1 (en) 2006-10-12 2020-01-08 The University of Queensland Compositions and methods for modulating immune responses
US20100152146A1 (en) * 2006-12-26 2010-06-17 Femmepharma Holding Company, Inc. Topical Administration of Danazol
US20080153789A1 (en) * 2006-12-26 2008-06-26 Femmepharma Holding Company, Inc. Topical administration of danazol
US20080160036A1 (en) * 2006-12-27 2008-07-03 Johns Hopkins University Compositions and methods for treating inflammation and auto-immune diseases
US20080206235A1 (en) * 2006-12-27 2008-08-28 Johns Hopkins University Compositions and methods for stimulating an immune response
US20090011444A1 (en) * 2006-12-27 2009-01-08 Johns Hopkins University Detection and diagnosis of inflammatory disorders
US7931896B2 (en) 2006-12-27 2011-04-26 The Johns Hopkins University Compositions and methods for treating inflammation and auto-immune diseases
US20090142342A1 (en) * 2006-12-27 2009-06-04 Johns Hopkins University B7-h4 receptor agonist compositions and methods for treating inflammation and auto-immune diseases
US20110171207A1 (en) * 2006-12-27 2011-07-14 The Johns Hopkins University Maryland Compositions and methods for treating inflammation and auto-immune diseases
US7989173B2 (en) 2006-12-27 2011-08-02 The Johns Hopkins University Detection and diagnosis of inflammatory disorders
US20110195073A1 (en) * 2006-12-27 2011-08-11 The Johns Hopkins University Compositions and methods for stimulating an immune response
US9134321B2 (en) 2006-12-27 2015-09-15 The Johns Hopkins University Detection and diagnosis of inflammatory disorders
US20080274979A1 (en) * 2007-03-14 2008-11-06 Rutledge Ellis-Behnke Treatment of leaky or damaged tight junctions and enhancing extracellular matrix
US9415084B2 (en) 2007-03-14 2016-08-16 Arch Biosurgery, Inc. Treatment of leaky or damaged tight junctions and enhancing extracellular matrix
US20080248999A1 (en) * 2007-04-04 2008-10-09 Biodel Inc. Amylin formulations
EP2581097A1 (en) 2007-04-25 2013-04-17 Arch Therapeutics, Inc Compositions for prevention of adhesions and other barrier applications
US8153595B2 (en) 2007-07-13 2012-04-10 The Johns Hopkins University B7-DC variants immunogenic compositions and methods of use thereof
US8445447B2 (en) 2007-07-13 2013-05-21 The Johns Hopkins University B7-DC variants immunogenic compositions and methods of use thereof
EP2514762A2 (en) 2007-07-13 2012-10-24 The Johns Hopkins University B7-DC variants
US20090042292A1 (en) * 2007-07-13 2009-02-12 The Johns Hopkins University B7-DC Variants
US8785396B2 (en) 2007-10-24 2014-07-22 Mannkind Corporation Method and composition for treating migraines
US20090175840A1 (en) * 2008-01-04 2009-07-09 Biodel, Inc. Insulin formulations for insulin release as a function of tissue glucose levels
US8877970B2 (en) 2008-01-09 2014-11-04 Molecular Insight Pharmaceuticals, Inc. Inhibitors of carbonic anhydrase IX
US8562945B2 (en) 2008-01-09 2013-10-22 Molecular Insight Pharmaceuticals, Inc. Technetium- and rhenium-bis(heteroaryl) complexes and methods of use thereof
US8962799B2 (en) 2008-01-09 2015-02-24 Molecular Insight Pharmaceuticals, Inc. Technetium—and rhenium-bis(heteroaryl) complexes and methods of use thereof
US20100183509A1 (en) * 2008-01-09 2010-07-22 Molecular Insight Pharmaceuticals, Inc. Technetium- and rhenium-bis(heteroaryl) complexes and methods of use thereof
US20090175794A1 (en) * 2008-01-09 2009-07-09 Molecular Insight Pharmaceuticals, Inc. Inhibitors of carbonic anhydrase ix
US9433594B2 (en) 2008-01-09 2016-09-06 Molecular Insight Pharmaceuticals, Inc. Technetium- and rhenium-bis(heteroaryl) complexes and methods of use thereof
US8840865B2 (en) 2008-01-09 2014-09-23 Molecular Insight Pharmaceuticals, Inc. Technetium- and rhenium-bis(heteroaryl) complexes and methods of use thereof
US20110020325A1 (en) * 2008-02-29 2011-01-27 Kwon Eugene D Methods for reducing granulomatous inflammation
US9446133B2 (en) 2008-06-13 2016-09-20 Mannkind Corporation Dry powder inhaler and system for drug delivery
US10751488B2 (en) 2008-06-13 2020-08-25 Mannkind Corporation Dry powder inhaler and system for drug delivery
US9192675B2 (en) 2008-06-13 2015-11-24 Mankind Corporation Dry powder inhaler and system for drug delivery
US10342938B2 (en) 2008-06-13 2019-07-09 Mannkind Corporation Dry powder drug delivery system
US9662461B2 (en) 2008-06-13 2017-05-30 Mannkind Corporation Dry powder drug delivery system and methods
US10201672B2 (en) 2008-06-13 2019-02-12 Mannkind Corporation Dry powder inhaler and system for drug delivery
US9339615B2 (en) 2008-06-13 2016-05-17 Mannkind Corporation Dry powder inhaler and system for drug delivery
US9511198B2 (en) 2008-06-13 2016-12-06 Mannkind Corporation Dry powder inhaler and system for drug delivery
US9364619B2 (en) 2008-06-20 2016-06-14 Mannkind Corporation Interactive apparatus and method for real-time profiling of inhalation efforts
US10675421B2 (en) 2008-06-20 2020-06-09 Mannkind Corporation Interactive apparatus and method for real-time profiling of inhalation efforts
US9943571B2 (en) 2008-08-11 2018-04-17 Mannkind Corporation Use of ultrarapid acting insulin
US8623817B2 (en) 2008-08-11 2014-01-07 Mannkind Corporation Method of treating diabetes type 2 by administering ultrarapid acting insulin
US8709416B2 (en) 2008-08-25 2014-04-29 Amplimmune, Inc. Compositions of PD-1 antagonists and methods of use
US20110195068A1 (en) * 2008-08-25 2011-08-11 Solomon Langermann Pd-1 antagonists and methods of use thereof
US8211401B2 (en) 2008-12-05 2012-07-03 Molecular Insight Pharmaceuticals, Inc. Technetium- and rhenium-bis(heteroaryl) complexes and methods of use thereof for inhibiting PSMA
US20100178246A1 (en) * 2008-12-05 2010-07-15 Molecular Insight Pharmaceuticals, Inc. Technetium- and rhenium-bis(heteroaryl) complexes and methods of use thereof for inhibiting psma
EP2706057A1 (en) 2008-12-05 2014-03-12 Molecular Insight Pharmaceuticals, Inc. Bis(imidazolyl)compounds and radionuclide complexes
US8211402B2 (en) 2008-12-05 2012-07-03 Molecular Insight Pharmaceuticals, Inc. CA-IX specific radiopharmaceuticals for the treatment and imaging of cancer
US9655850B2 (en) 2008-12-29 2017-05-23 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
US9220687B2 (en) 2008-12-29 2015-12-29 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
US10172850B2 (en) 2008-12-29 2019-01-08 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
US9060927B2 (en) 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
US9983108B2 (en) 2009-03-11 2018-05-29 Mannkind Corporation Apparatus, system and method for measuring resistance of an inhaler
US9630930B2 (en) 2009-06-12 2017-04-25 Mannkind Corporation Diketopiperazine microparticles with defined specific surface areas
US9149547B2 (en) 2009-06-15 2015-10-06 Molecular Insight Pharmaceuticals, Inc. Process for production of heterodimers of glutamic acid
US20110003000A1 (en) * 2009-07-06 2011-01-06 Femmepharma Holding Company, Inc. Transvaginal Delivery of Drugs
WO2011005756A1 (en) 2009-07-06 2011-01-13 Puretech Ventures, Llc Delivery of agents targeted to microbiota niches
US9011853B2 (en) 2009-08-31 2015-04-21 Amplimmune, Inc. B7-H4 fusion proteins and methods of use thereof
US9957312B2 (en) 2009-08-31 2018-05-01 Medimmune, Llc B7-H4 fusion proteins and methods of use thereof
US9005616B2 (en) 2009-08-31 2015-04-14 Amplimmune, Inc. Methods and compositions for the inhibition of transplant rejection
US9706944B2 (en) 2009-11-03 2017-07-18 Mannkind Corporation Apparatus and method for simulating inhalation efforts
US9439941B2 (en) 2009-12-14 2016-09-13 The University Of Hong Kong Nano cancer barrier device (NCBD) to immobilize and inhibit the division of metastic cancer stem cells
WO2012058715A1 (en) 2010-11-01 2012-05-10 University Of Technology, Sydney Immune-modulating agents and uses therefor
US10625034B2 (en) 2011-04-01 2020-04-21 Mannkind Corporation Blister package for pharmaceutical cartridges
US10130709B2 (en) 2011-06-17 2018-11-20 Mannkind Corporation High capacity diketopiperazine microparticles and methods
US9364436B2 (en) 2011-06-17 2016-06-14 Mannkind Corporation High capacity diketopiperazine microparticles and methods
US9233159B2 (en) 2011-10-24 2016-01-12 Mannkind Corporation Methods and compositions for treating pain
US10258664B2 (en) 2011-10-24 2019-04-16 Mannkind Corporation Methods and compositions for treating pain
US9610351B2 (en) 2011-10-24 2017-04-04 Mannkind Corporation Methods and compositions for treating pain
US9422251B2 (en) 2012-01-06 2016-08-23 Molecular Insight Pharmaceuticals, Inc. Metal complexes of poly(carboxyl)amine-containing ligands having an affinity for carbonic anhydrase IX
US9120837B2 (en) 2012-01-06 2015-09-01 Molecular Insight Pharmaceuticals Metal complexes of poly(carboxyl)amine-containing ligands having an affinity for carbonic anhydrase IX
US9802012B2 (en) 2012-07-12 2017-10-31 Mannkind Corporation Dry powder drug delivery system and methods
US10159644B2 (en) 2012-10-26 2018-12-25 Mannkind Corporation Inhalable vaccine compositions and methods
US10201624B2 (en) 2013-01-14 2019-02-12 Molecular Insight Pharmaceuticals, Inc. Triazine based radiopharmaceuticals and radioimaging agents
US10086096B2 (en) 2013-01-14 2018-10-02 Molecular Insight Pharmaceuticals, Inc. Triazine based radiopharmaceuticals and radioimaging agents
US11712485B2 (en) 2013-01-14 2023-08-01 Molecular Insight Pharmaceuticals, Inc. Triazine based radiopharmaceuticals and radioimaging agents
US10898598B2 (en) 2013-01-14 2021-01-26 Molecular Insight Pharmaceuticals, Inc. Triazine based radiopharmaceuticals and radioimaging agents
US10167336B2 (en) 2013-03-14 2019-01-01 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
US10421729B2 (en) 2013-03-15 2019-09-24 Mannkind Corporation Microcrystalline diketopiperazine compositions and methods
US9925144B2 (en) 2013-07-18 2018-03-27 Mannkind Corporation Heat-stable dry powder pharmaceutical compositions and methods
US11446127B2 (en) 2013-08-05 2022-09-20 Mannkind Corporation Insufflation apparatus and methods
US9339476B2 (en) 2013-08-22 2016-05-17 Arch Biosurgery, Inc. Implantable meshes for controlling the movement of fluids
US10314886B2 (en) 2013-08-22 2019-06-11 Arch Biosurgery, Inc. Implantable meshes for controlling the movement of fluids
US9821022B2 (en) 2013-08-22 2017-11-21 Arch Biosurgery, Inc. Implantable meshes for controlling the movement of fluids
US10869907B2 (en) 2013-08-22 2020-12-22 Arch Biosurgery, Inc. Implantable meshes for controlling the movement of fluids
US11136393B2 (en) 2013-10-01 2021-10-05 Mayo Foundation For Medical Education And Research Methods for treating cancer in patients with elevated levels of Bim
US10259875B2 (en) 2013-10-01 2019-04-16 Mayo Foundation For Medical Education And Research Methods for treating cancer in patients with elevated levels of BIM
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
US10302653B2 (en) 2014-05-22 2019-05-28 Mayo Foundation For Medical Education And Research Distinguishing antagonistic and agonistic anti B7-H1 antibodies
EP4198059A1 (en) 2014-05-27 2023-06-21 The University of Queensland Modulation of cellular stress
WO2015179918A1 (en) 2014-05-27 2015-12-03 The University Of Queensland Modulation of cellular stress
US10517875B2 (en) 2014-07-23 2019-12-31 Mayo Foundation for Medical Engineering and Research Targeting DNA-PKcs and B7-H1 to treat cancer
US11504376B2 (en) 2014-07-23 2022-11-22 Mayo Foundation For Medical Education And Research Targeting DNA-PKCS and B7-H1 to treat cancer
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
US10875923B2 (en) 2015-10-30 2020-12-29 Mayo Foundation For Medical Education And Research Antibodies to B7-H1
WO2019236669A1 (en) * 2018-06-08 2019-12-12 The United States Of America, As Represented By The Secretary Of Agriculture Compositions containing microencapsulated organic compounds

Similar Documents

Publication Publication Date Title
US4272398A (en) Microencapsulation process
US5466460A (en) Controlled release microcapsules
US4376113A (en) Stable suspensions and powders of stable microcapsules and their preparation
CA2294332C (en) Microparticles containing agricultural active ingredients
US5639710A (en) Solid microspheres for agriculturally active compounds and process for their production
AU2002340552B2 (en) Active material immobilized in stable hydrogel microbeads
US5643351A (en) Encapsulation with water soluble polymer
KR100420287B1 (en) Process for producing dry water dispersible compositions of microencapsulated pesticides and composition produced therefrom
JP2003512395A (en) Encapsulated active substance immobilized in hydrogel microbeads
US5788991A (en) Coated microparticle agglomerates
JPS6332043B2 (en)
Mishra et al. Polymer Formulations for Pesticide Release
JP2002066307A (en) Microcapsule granular material and method of manufacturing the same
JPH0967205A (en) Granular agrochemical composition and its production
US5773030A (en) Multiply-coated particles
JPS62215504A (en) Agricultural, insecticidal and acaricidal composition
JP3567543B2 (en) Method for producing pesticide composition
JP3567544B2 (en) Pesticide composition and method for producing the same
JPH0356403A (en) Controlled release device for active ingredient
BR9803712B1 (en) CONTROLLED RELEASE COMPOSITION TO PROVIDE AN AGRICULTURAL CHEMICAL PRODUCT FOR A PLANT, PROCESS TO PROVIDE A TRIZOLIC FUNGICIDE TO A PLANT AND PROCESS FOR PRODUCTION OF SUCH COMPOSITION.

Legal Events

Date Code Title Description
STCF Information on status: patent grant

Free format text: PATENTED CASE